SPAF-III Trial

Summary: Evaluated warfarin (goal INR 1.2 to 1.5) AND aspirin versus warfarin alone (goal INR 2-3) in patients with atrial fibrillation for primary event of stroke and systemic embolization. Warfarin with goal INR 1.2 to 1.5 AND aspirin inferior to warfarin alone with goal INR 2-3 superior to (7.9%/yr primary event versus 1.9%.yr). There was an increased risk of disabling stroke and vascular death with warfarin AND aspirin.

Original Publication:

Lancet. 1996 Sep 7;348(9028):633-8.

Circulation. 2004 Oct 19;110(16):2287-92.

http://www.ncbi.nlm.nih.gov/pubmed/1860198

Eponym: Stroke Prevention in Atrial Fibrillation Study III